- Conditions
- Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma, Myeloid Malignancies, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome
- Interventions
- PRT2527, Zanubrutinib, Venetoclax
- Drug
- Lead sponsor
- Prelude Therapeutics Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 5
- States / cities
- Duarte, California • Bethesda, Maryland • Boston, Massachusetts + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1441–1464
of 12,239
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Skin Cancer, Basal Cell Cancer, Squamous Cell Carcinoma, Melanoma (Skin Cancer), Melanoma In Situ, Melanoma Detection, Melanoma
- Interventions
- DermaSensor
- Device
- Lead sponsor
- DermaSensor, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Pediatric Obesity, Food Insecurity, Nutrition, Healthy, Nutrition Poor
- Interventions
- Grocery intervention - unrestricted, Grocery intervention - restricted
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 12 Months to 24 Months
- Enrollment
- 228 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Multiple Myeloma
- Interventions
- bb2121
- Biological
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 9
- States / cities
- Stanford, California • Bethesda, Maryland • Boston, Massachusetts + 4 more
- Conditions
- Multiple Sclerosis
- Interventions
- megadose oral methylprednisolone, IV methylprednisolone
- Drug
- Lead sponsor
- Fred Lublin
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 10
- States / cities
- New Brunswick, New Jersey • Brooklyn, New York • Buffalo, New York + 3 more
- Conditions
- Cancer of the Prostate, Neoplasms, Prostate, Prostate Cancer, Prostatic Cancer, Neoplasms, Prostatic, Prostate Neoplasms, Castration-resistant
- Interventions
- ASN001: Escalating dose Part A
- Drug
- Lead sponsor
- Asana BioSciences
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Detroit, Michigan • Cleveland, Ohio + 3 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- ACTOS (Pioglitazone)
- Drug
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hypohidrotic Ectodermal Dysplasia
- Interventions
- Not listed
- Lead sponsor
- Edimer Pharmaceuticals
- Industry
- Eligibility
- 14 Years to 29 Years · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Gingival Recession
- Interventions
- Acellular Dermal Matrix
- Biological
- Lead sponsor
- Tufts University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Obesity, Type 2 Diabetes Mellitus (T2DM)
- Interventions
- K-757 and K-833 QD, K-757 and K-833 BID, Matching placebo to K-757 and K-833 QD, Matching placebo to K-757 and K-833 BID
- Drug
- Lead sponsor
- TriGemX Bio, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Gastroenteritis
- Interventions
- HIL-214, Placebo
- Biological
- Lead sponsor
- HilleVax
- Industry
- Eligibility
- 2 Months to 2 Months
- Enrollment
- 329 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 7
- States / cities
- Lafayette, Louisiana • Missoula, Montana • Hastings, Nebraska + 4 more
- Conditions
- Solid Tumors, Non-small Cell Lung Carcinoma
- Interventions
- DS-2248
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 9
- States / cities
- Duarte, California • Loma Linda, California • Orange, California + 6 more
- Conditions
- Sickle Cell Disease
- Interventions
- I-STRONG, Enhanced Usual Care (EUC)
- Behavioral · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Hartford, Connecticut • Atlanta, Georgia • Cincinnati, Ohio
- Conditions
- Cardiogenic Shock, Acute Myocardial Infarction
- Interventions
- Not listed
- Lead sponsor
- STAVROS G DRAKOS
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Weston, Florida • Falls Church, Virginia
- Conditions
- Lymphoma
- Interventions
- forodesine hydrochloride
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Hot Springs, Arkansas • Stanford, California + 7 more
- Conditions
- Advanced Cervical Adenocarcinoma, Advanced Vaginal Carcinoma, Advanced Vulvar Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma, Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma, Metastatic Cervical Adenocarcinoma, Metastatic Cervical Carcinoma, Metastatic Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Metastatic Vaginal Adenocarcinoma, Metastatic Vaginal Carcinoma, Metastatic Vulvar Carcinoma, Recurrent Cervical Adenocarcinoma, Recurrent Cervical Carcinoma, Recurrent Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Stage III Cervical Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Vulvar Cancer AJCC v8, Stage IIIC Vulvar Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Adenocarcinoma, Vulvar Squamous Cell Carcinoma
- Interventions
- Durvalumab, Laboratory Biomarker Analysis, Stereotactic Radiosurgery, Tremelimumab
- Biological · Other · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Houston, Texas
- Conditions
- Hematological Malignancy, Multiple Myeloma
- Interventions
- Evomela, Fludarabine, Total Body Irradiation, Haploidentical Hematopoietic Cell Transplantation
- Drug · Radiation · Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Diabetes Mellitus
- Interventions
- Enhanced CGM Interventions, Standard of Care
- Other
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Multiple Sclerosis
- Interventions
- PIPE-791, Placebo
- Drug
- Lead sponsor
- Contineum Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD)
- Interventions
- ABBV-932, Placebo for ABBV-932
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Los Alamitos, California • Grayslake, Illinois • Marlton, New Jersey
- Conditions
- Myotonic Dystrophy 1
- Interventions
- ATX-01, Placebo
- Drug
- Lead sponsor
- ARTHEx Biotech S.L.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Gainesville, Florida • Iowa City, Iowa + 2 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- GFF MDI, GP MDI, FF MDI, Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®), Placebo MDI
- Drug
- Lead sponsor
- Pearl Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 2,103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 121
- States / cities
- Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 118 more
- Conditions
- Multiple Myeloma
- Interventions
- Vorinostat, Bortezomib, pegylated liposomal doxorubicin
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Atrial Fibrillation
- Interventions
- Vernakalant (oral), Placebo comparator
- Drug
- Lead sponsor
- Advanz Pharma
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 4
- States / cities
- Huntsville, Alabama • Walnut Creek, California • Hershey, Pennsylvania + 1 more